TSC2 and breast carcinoma: This result is supported by the observation that breast cancer cells can bypass hypoxia-mediated inhibition of protein synthesis through gene silencing of 4E-BP1, eEF2 kinase or tuberous sclerosis complex 2 (TSC2), maintaining a continuous requirement of translational machinery [59].